Real-World Data Comparing Third and Subsequent Line Regimens for Treatment of Metastatic Triple-Negative Breast Cancer in the United States

Eribulin is a commonly prescribed regimen for mTNBC patients pre-treated with one or more chemotherapy regimens, although no clear survival benefit has been shown when compared to treatment of physician’s choice. The authors used real-world oncology data to compare the impact of treatment with eribulin vs. other common chemotherapies and found no survival benefit with eribulin in third line and subsequent lines of therapy.